HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement GMPs, NDI Guidance Should Top CFSAN 2007 Priority List – CRN

This article was originally published in The Tan Sheet

Executive Summary

The Council for Responsible Nutrition urges FDA's Center for Food Safety & Applied Nutrition to make the publication of the good manufacturing practices for dietary supplements final rule a prominent program priority for 2007

You may also be interested in...



FDA Requiring GRAS-Level Safety Standards For NDI Submissions, Experts Say

FDA has gradually raised the safety standard for new dietary ingredients above the level intended by DSHEA, according to several experts

CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More

FDA should accept safety findings from outside expert panels when reviewing new dietary ingredient notifications, CHPA says in Aug. 25 comments on CFSAN priorities

Dietary Supplement Reps Ask FDA For Clarity Across The Board On NDIs

FDA should focus the 75-day premarket notification process specifically on ingredients, not finished products, industry stakeholders asserted at the agency's public meeting on new dietary ingredient (NDI) submissions Nov. 15

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel